Insight Molecular Diagnostics Inc. (IMDX) Stock Score, Valuation & Financial Research
Insight Molecular Diagnostics Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 21/100.
Quick answer for IMDX
Insight Molecular Diagnostics Inc. currently has a Wall Street Score of 21/100. The stored market price is $4.02. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is -0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What Insight Molecular Diagnostics Inc. does
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for inte
IMDX financial snapshot
- Wall Street Score:
- 21/100
- Current price:
- $4.02
- Market capitalization:
- $129.8M
- Revenue:
- $1.7M
- Net income:
- $-49.4M
- Free cash flow:
- $-25.4M
- Cash:
- $17.8M
- Total debt:
- $2.6M
- EPS:
- -1.65
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is -0.6%.
- Free cash flow is $-25.4M, showing cash burn in the current stored period.
- The balance sheet shows $17.8M of cash versus $2.6M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.2 points: IMDX decreased 0.2 points because some fundamentals weakened.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research IMDX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.